Skip to Content

Drug Interactions between Genvoya and Stribild

This report displays the potential drug interactions for the following 2 drugs:

  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide)
  • Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir)

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tenofovir cobicistat

Applies to: Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir) and Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)

Using cobicistat together with tenofovir can increase the effects of tenofovir, which can cause new or worse kidney problems. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

emtricitabine cobicistat

Applies to: Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir) and Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)

Cobicistat is a medication used to boost the effects of some medications that treat HIV infection. However, using cobicistat together with other HIV medications, such as emtricitabine, may alter the blood levels and effects of both medications. Using emtricitabine with cobicistat may reduce or increase blood levels of cobicistat. Reduced blood levels of cobicistat may make cobicistat less effective and may cause overall HIV treatment to be less effective. Cobicistat may increase blood levels of emtricitabine which may increase the risk of side effects. Talk to your doctor or pharmacist if you have any questions on how to use these medications properly. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

elvitegravir food

Applies to: Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)

Food significantly increases the absorption of elvitegravir. You should take each dose of elvitegravir with a meal. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication in treating HIV infection.

Switch to professional interaction data

Minor

tenofovir food

Applies to: Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

For clinical details see professional interaction data.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Antiviral boosters

Therapeutic duplication

The recommended maximum number of medicines in the 'antiviral boosters' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'antiviral boosters' category:

  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide)
  • Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Duplication

Integrase strand transfer inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'integrase strand transfer inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'integrase strand transfer inhibitors' category:

  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide)
  • Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide